Published in Br J Cancer on April 24, 2012
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 1.13
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther (2013) 1.05
A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Rep (2013) 0.99
Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells. Cell Death Dis (2014) 0.96
Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene (2015) 0.86
Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene (2016) 0.86
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem (2012) 0.85
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res (2015) 0.83
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death Dis (2016) 0.83
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. BMC Cancer (2014) 0.80
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer (2014) 0.79
Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer. Oncol Rep (2014) 0.78
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. J Exp Clin Cancer Res (2014) 0.78
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget (2015) 0.77
Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET. Mol Imaging Biol (2013) 0.77
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol (2014) 0.76
Single amino acid arginine deprivation triggers prosurvival autophagic response in ovarian carcinoma SKOV3. Biomed Res Int (2014) 0.76
Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther (2015) 0.76
Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. J Pathol Clin Res (2014) 0.76
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability. Oncotarget (2016) 0.75
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res (2009) 1.88
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol (2004) 1.83
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des (2008) 1.82
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 1.78
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res (2002) 1.73
Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem (2003) 1.69
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res (2006) 1.42
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer (2007) 1.39
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther (2009) 1.37
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer (2008) 1.36
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med (2010) 1.21
In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int J Cancer (1992) 1.20
Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs (2004) 1.16
Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release (2002) 1.15
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
I. Arginine. Biomed Pharmacother (2002) 1.11
The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined? Br J Haematol (2004) 1.08
Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology (2003) 1.04
Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett (2003) 1.04
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights (2007) 0.96
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun (2010) 0.92
Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep (2007) 0.89
Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer (2003) 0.87
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell (1994) 2.84
Estimating the cots required for neonatal intensive care. Arch Dis Child (1981) 2.73
DNA methylation: correlation with DNase I sensitivity of chicken ovalbumin and conalbumin chromatin. Nucleic Acids Res (1979) 2.31
Islet-cell antibodies in diabetes mellitus. Lancet (1976) 2.20
Ossifying fibromas of the jaw bone: 20 cases. Dentomaxillofac Radiol (2010) 2.15
Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol (1995) 2.14
Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J (2001) 2.06
Incidence of familial melanoma and MLM2 gene. Lancet (1994) 2.03
Recovery of left ventricular function following early reperfusion in acute myocardial infarction: a potential role for the calcium antagonist nisoldipine. Cardiovasc Drugs Ther (1997) 2.03
Xanthogranulomatous pyelonephritis: experience in 36 cases. J Urol (1992) 2.02
Apaf-1 oligomerizes into biologically active approximately 700-kDa and inactive approximately 1.4-MDa apoptosome complexes. J Biol Chem (2000) 1.94
Differential nuclease sensitivity of the ovalbumin and beta-globin chromatin regions in erythrocytes and oviduct cells of laying hen. Nucleic Acids Res (1980) 1.91
Prevalence and risk factors for meticillin-resistant Staphylococcus aureus in adult emergency admissions--a case for screening all patients? J Hosp Infect (2007) 1.89
When do pregnant women attend for antenatal care? Br Med J (1980) 1.88
Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res (1991) 1.88
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des (2008) 1.82
Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol (2000) 1.68
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J (1974) 1.64
Feasibility and psychometric properties of using peers, consulting physicians, co-workers, and patients to assess physicians. Acad Med (1997) 1.61
Mitochondrial antibodies (AMA). Gut (1974) 1.60
Measurement of glycosylated hemoglobin on cellulose acetate membranes by mobile affinity electrophoresis. Clin Chem (1983) 1.58
Ultrasonography for inguinal hernias in boys. J Pediatr Surg (1998) 1.55
The morbidity of long-term seizure monitoring using subdural strip electrodes. J Neurosurg (1991) 1.53
Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry (2001) 1.52
Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants. Arch Dis Child Fetal Neonatal Ed (2002) 1.48
Vascular access for hemodialysis in children. Pediatr Nephrol (1997) 1.48
Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med (1990) 1.48
Who cares for Missouri's Medicaid nursing home residents? Characteristics of attending physicians. J Am Geriatr Soc (1993) 1.47
Immunopathology of liver disease. Prog Liver Dis (1972) 1.47
Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut (1974) 1.47
Retrograde transcatheter occlusion of patent ductus arteriosus: preliminary experience in Gianturco coil technique without heparinization. J Invasive Cardiol (2001) 1.42
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives. J Med Chem (1993) 1.41
Detection of occult bone metastasis by MRI scan. J Fla Med Assoc (1990) 1.40
Spontaneous resolution of cystic hygroma in a 46,XX normal female. Prenat Diagn (1990) 1.40
Risk of miscarriage and a common variant of the estrogen receptor gene. Am J Epidemiol (1993) 1.39
Islet-cell antibodies in juvenile diabetes mellitus of recent onset. Lancet (1975) 1.38
Acid resistance of enamel subsurface lesions remineralized by a sugar-free chewing gum containing casein phosphopeptide-amorphous calcium phosphate. Caries Res (2004) 1.38
ON THE LACK OF EVIDENCE OF TRANSMISSION BY HUMAN BEINGS OF TUBERCULOSIS DUE TO THE BOVINE TYPE OF BACILLUS. Br Med J (1934) 1.38
Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res (1997) 1.36
The dynamics of interorganizational coordination. Adm Sci Q (1984) 1.35
Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sci U S A (1994) 1.33
Release of free bases from deoxyribonucleic acid after reaction with bleomycin. Mol Pharmacol (1972) 1.33
Plasma prednisolone levels and adrenocortical responsiveness after administration of prednisolone-21-phosphate as a retention enema. Gut (1979) 1.32
The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem (2000) 1.32
Gene expression signatures identify novel regulatory pathways during murine lung development: implications for lung tumorigenesis. J Med Genet (2003) 1.31
Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem (1996) 1.31
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Distributed situation awareness in dynamic systems: theoretical development and application of an ergonomics methodology. Ergonomics (2006) 1.29
Reovirus sigmaNS protein is required for nucleation of viral assembly complexes and formation of viral inclusions. J Virol (2001) 1.29
AN IMMUNOLOGICAL STUDY OF THE A SUBSTANCE OR ACETYL POLYSACCHARIDE OF PNEUMOCOCCUS TYPE I. J Exp Med (1934) 1.27
Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol (2002) 1.26
Primary angioplasty in acute inferior myocardial infarction with anomalous-origin right coronary arteries as infarct-related arteries: focus on anatomic and clinical features, outcomes, selection of guiding catheters and management. J Invasive Cardiol (2001) 1.25
Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol (1999) 1.24
Localization of sequences specifying messenger RNA to light-staining G-bands of human chromosomes. Chromosoma (1977) 1.24
Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood (2001) 1.24
Identification of candidate lung cancer susceptibility genes in mouse using oligonucleotide arrays. J Med Genet (2002) 1.23
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med (2010) 1.21
Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis. Blood (1998) 1.18
I. Sarcoma of the Kidney in Children: A Critical Review of the Pathology, Symptomatology, Prognosis, and Operative Treatment as seen in One Hundred and Forty-five Cases. Ann Surg (1897) 1.16
Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis (2013) 1.16
Activation of mitogen-activated protein (MAP) kinase pathway by pervanadate, a potent inhibitor of tyrosine phosphatases. J Biol Chem (1996) 1.14
Prebiotic concept for infant nutrition. Acta Paediatr Suppl (2003) 1.14
The epidemiology of multiple births. Hum Reprod Update (1999) 1.13
[Cutaneous leishmaniasis]. Hautarzt (2008) 1.13
Ultrastructural changes in the small intestine induced by ethanol. Gastroenterology (1972) 1.12
Rectally administered prednisolone--evidence for a predominantly local action. Gut (1980) 1.12
The fine structure of the frontal filament complex of barnacle larvae (Crustacea: cirripedia). Cell Tissue Res (1974) 1.11
Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A (1996) 1.11
Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol (1998) 1.11
MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica (2008) 1.10
Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry (1997) 1.10
Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan. Lupus (2009) 1.10
Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Biochemistry (1996) 1.09
A lymphoma plasma membrane-associated protein with ankyrin-like properties. J Cell Biol (1986) 1.08
Drug resistance in brain tumors. J Neurooncol (1994) 1.08
A case of testicular lupus. Lupus (2000) 1.07
A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res (2000) 1.07
Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol (1999) 1.07
What do patients and their carers want to know about stroke? A two-year follow-up study. Clin Rehabil (1998) 1.07
Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol (1990) 1.07
Sequence diversity within the reovirus S2 gene: reovirus genes reassort in nature, and their termini are predicted to form a panhandle motif. J Virol (1994) 1.06
Periprosthetic metastatic carcinoma. Pitfalls in the management of two cases initially diagnosed as osteolysis. J Arthroplasty (1996) 1.06
Preferential damage of active chromatin by bleomycin. Cancer Res (1981) 1.06
Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer (2011) 1.05
Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem (1998) 1.05